This report was first published by Endpoints News. To see the original version, click here
Flagship’s Tessera Therapeutics confirmed that it will begin its first human trial next month for its in vivo gene writing platform in the crowded field of adults with severe alpha-1 antitrypsin deficiency (AATD).
The well-funded Boston biotech is conducting a Phase 1/2, open-label, multi-center trial in 72 patients to evaluate the safety, tolerability, and efficacy of the therapy, known as TSRA-196, in adults with the PiZZ genotype who have lung and/or liver disease associated with AATD.
您已閱讀47%（582字），剩余53%（668字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。